150 related articles for article (PubMed ID: 17975981)
21. Experimental intraprostatic injection of bacillus Calmette-Guerin: a feasibility and safety study.
Kosecka U; Sowery RD; Morales A
J Urol; 2005 Mar; 173(3):996-9. PubMed ID: 15711364
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors.
Spugnini EP; Vincenzi B; Baldi F; Citro G; Baldi A
Anticancer Res; 2006; 26(6B):4585-9. PubMed ID: 17201181
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
[TBL] [Abstract][Full Text] [Related]
25. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
26. Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs.
Rassnick KM; Al-Sarraf R; Bailey DB; Chretin JD; Phillips B; Zwhalen CH
Vet Comp Oncol; 2010 Jun; 8(2):103-11. PubMed ID: 20579323
[TBL] [Abstract][Full Text] [Related]
27. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
28. Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy.
Skolarus TA; Lee EW; Virgo KS; Katz MD; Hudson MA; Kibel AS; Grubb RL
J Am Coll Surg; 2009 Aug; 209(2):248-53. PubMed ID: 19632602
[TBL] [Abstract][Full Text] [Related]
29. The present status of BCG treatment in the veterinary practice.
Klein WR; Rutten VP; Steerenberg PA; Ruitenberg EJ
In Vivo; 1991; 5(6):605-8. PubMed ID: 1810446
[TBL] [Abstract][Full Text] [Related]
30. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?
Damiano R; De Sio M; Quarto G; Di Lorenzo G; Perdonà S; Palumbo IM; Azzarito G; Giugliano F; Autorino R
BJU Int; 2009 Sep; 104(5):633-9. PubMed ID: 19298412
[TBL] [Abstract][Full Text] [Related]
31. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
[TBL] [Abstract][Full Text] [Related]
32. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
Taylor F; Gear R; Hoather T; Dobson J
J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
[TBL] [Abstract][Full Text] [Related]
33. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
[TBL] [Abstract][Full Text] [Related]
34. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Elders RC; Baines SJ; Catchpole B
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy using intratumoral bacillus Calmette-Guerin (BCG) and vincristine in dogs with transmissible venereal tumours: therapeutic efficacy and histological changes.
Mukaratirwa S; Chitanga S; Chimatira T; Makuleke C; Sayi ST; Bhebhe E
J S Afr Vet Assoc; 2009 Jun; 80(2):92-6. PubMed ID: 19831270
[TBL] [Abstract][Full Text] [Related]
37. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.
Bisiaux A; Thiounn N; Timsit MO; Eladaoui A; Chang HH; Mapes J; Mogenet A; Bresson JL; Prié D; Béchet S; Baron C; Sadorge C; Thomas S; Albert EB; Albert PS; Albert ML
J Urol; 2009 Apr; 181(4):1571-80. PubMed ID: 19230924
[TBL] [Abstract][Full Text] [Related]
38. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
Agrawal MS; Agrawal M; Bansal S; Agarwal M; Lavania P; Goyal J
Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
[TBL] [Abstract][Full Text] [Related]
39. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment.
Welle MM; Bley CR; Howard J; Rüfenacht S
Vet Dermatol; 2008 Dec; 19(6):321-39. PubMed ID: 18980632
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of buffy coat smears for circulating mast cells in healthy cats and ill cats without mast cell tumor-related disease.
Garrett LD; Craig CL; Szladovits B; Chun R
J Am Vet Med Assoc; 2007 Dec; 231(11):1685-7. PubMed ID: 18052803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
